The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Aptamers: Therapeutics, Technologies and Services Market, Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2022

  • Pages
    350

  • View Count
    330

Example Insights

Aptamers-Therapeutics-Technologies-and-Services-Market-Context-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Therapeutic-Candidates-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Distribution-by-Type-of-Aptamer-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Very-Large-Companies-thumb
Aptamers-Therapeutics-Technologies-and-Services-Market-Distribution-of-Instances-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Year-wise-Trend-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Clinical-Trial-Analysis-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Technology-Providers-thumb
	Aptamers-Therapeutics-Technologies-and-Services-Market-Competitiveness-Analysis-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Stat-up-Benchmarking-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Year-of-Publication-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Grant-Analysis-thumb
Aptamers-Therapeutics-Technologies-and-Services-Market-Publication-Analysis-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-List-of-Aptamer-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Bubble-Chart-Analysis-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Future-Clinical-Demand-thumb
Aptamers-Therapeutics-Technologies-and-Services-Market-Market-Forecast-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Focus-Area-thumb Aptamers-Therapeutics-Technologies-and-Services-Market-Application-Area-thumb

 

Overview

Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales (USD 200 million) of the aforementioned product further bolstered the confidence of industry stakeholders in this new therapeutic modality, creating lucrative opportunity for therapy developers. Further, over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity. Given the various advantages, aptamer-based therapeutics in the current pipeline are targeting a range of therapeutic areas, such as oncological disorders, ophthalmological disorders and metabolomic disorders. It is worth mentioning that, in order to further enhance their performance, aptamers can be linked with various diagnostic agents, using physical or chemical conjugation. Moreover, to ensure the development of more effective therapy candidates, several players have developed novel aptamer-based technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment. In addition, post the onset of COVID-19 pandemic, there has been a significant rise in the demand for COVID-19 testing kits, which has prompted several companies to develop aptamer-based diagnostic tools for the detection of SARS-CoV-2. Consequently, to support the various initiatives undertaken by industry players, investments worth over USD 1.3 billion have been reported in the past five years. 

Presently, a significant portion of the existing manufacturing capabilities and expertise in this domain belongs to more than 50 contract service providers. Therefore, several researchers and therapy / diagnostic developers prefer to outsource their aptamer manufacturing operations. Given the rise in global disease burden over the past few years, there has been an evident increase in the demand for effective targeted therapies along with novel diagnostic approaches to reduce development timelines and investments. We believe that, with an increase in the number of aptamer-based therapies being developed and subsequent advancement of therapies across various stages of clinical trials, and their eventual commercialization, the opportunities for custom / contract service providers is likely to increase in the foreseen future. Overall, aptamer therapeutics, technologies and services market is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The “Aptamers: Therapeutics, Technologies and Services Market, Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential associated with the aptamer-based therapies, technologies and services market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics, along with information on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers, L-RNA aptamers and peptide aptamers), location of headquarters, phase of development (discovery, pre-clinical, clinical and approved), line of treatment (1st and 2nd line of treatment), mechanism of action, route of administration (intravenous, intravitreal and subcutaneous), type of therapy (monotherapy and combinational therapy), therapeutic area (bleeding disorders, bone disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders and ophthalmological disorders) and target indication (geographic atrophy, macular degeneration, stroke, acute stroke, ischemic stroke, multiple myeloma, chronic lymphocytic leukemia, metastatic pancreatic cancer and others).
  • A detailed overview of the current market landscape of players engaged in the development of aptamer-based technologies, based on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers and peptide aptamers), location of headquarters, status of development (concept, under development and commercialized), type of technology used (SELEX, NGS, ELISA and others), application area (research, diagnostic and therapeutic purposes), purpose of technology (Characterization, drug discovery, drug development, identification, biomarker discovery, assay, validation and others), type of analyte (serum, plasma, saliva and others), therapeutic area (autoimmune disorders, infectious disorders, neurodegenerative disorders, neurological disorders, antibiotic resistance, bone disorders, CNS disorders, genetic disorders, infectious diseases, nephrological disorders, oncological disorders, ophthalmological disorders, oral diseases and psychological disorders) and target indication (amyotrophic lateral sclerosis,  breast cancer ,  colon cancer,  dengue virus,  liver cancer,  prostate cancer, porcine reproductive and respiratory syndrome virus (PRRSv), mycoplasma hyopneumoniae,  stomach cancer and others).
  • A detailed overview of the current market landscape of aptamer-based service providers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service provider (contract research organizations, contract manufacturing organizations and third-party service providers), scale of operation (small, medium and large scale), area of application (therapeutic, diagnostic and others), type of technology used (ELISA, NGS, SELEX and others), type of technology platform (computational and others), and types of analysis offered (discovery, screening, characterization, synthesis, modification and purification).
  • A detailed competitiveness analysis of aptamer-based service providers, based on several relevant parameters, such as supplier strength (in terms of years of experience), portfolio strength (in terms of number of services offered) and portfolio diversity (based on scale of operation, area of application, technology used and types of analysis offered).
  • An insightful competitiveness analysis of aptamer-based technologies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on type of aptamer, status of development, area of application, type of technology used and purpose of technology).
  • An insightful product competitiveness analysis, benchmarking aptamer-based therapies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on phase of development, line of treatment, type of therapy, route of administration and target indication).
  • An analysis on the recent developments within the aptamers industry, highlighting information on several partnerships and collaborations that have been established in this domain, during the period 2016-2021. 
  • A detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in this domain, during the period 2016-2021.
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects focused on aptamers, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
  • A detailed review of close to 390 peer-reviewed, scientific articles related to research on aptamers, based on several parameters, such as year of publication, type of publication, and popular keywords. The chapter also provides information on the top journals, top institutes and top authors (in terms of number of articles published).
  • An in-depth analysis of patents related to aptamer-based therapies and technologies, filed / granted since 2016, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players and regional distribution of trials.
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of technologies offered, type of aptamer, status of development, area of application, type of technology used and purpose of technology.
  • Elaborate profiles of prominent players (shortlisted based our proprietary scoring criteria) engaged in this domain. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key executives. It also includes details on their respective product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent technologies (shortlisted based our proprietary scoring criteria) developed by players engaged in this domain. Each technology profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details on their respective technology portfolio, recent developments and an informed future outlook.
  • An informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics, taking into account the target patient population in ongoing and planned clinical trials focused on aptamer-based therapies, sponsored by both industry and non-industry players.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the aptamer-based therapies, technologies and services market. We have provided an informed estimate of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] application area (therapeutics, research and diagnostics), [B] type of aptamer (DNA, RNA and peptide), [C] target indication (geographic atrophy, macular degeneration, Von Willebrand diseases, hemophilia A), [D] route of administration (intravitreal, intravenous, subcutaneous), [E] scale of operation (clinical and commercial), [F] focus area (product development, product commercialization, technology integration, technology utilization and others), [G] company size (very small, small, mid-sized, large and very large) and [H] key geographical regions (North America, Europe, Asia-Pacific And Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.

Key Questions Answered

  • Who are the key players engaged in the development of aptamer-based therapeutics and technologies?
  • Which are the key drugs being evaluated across early and late stages of development?
  • Which companies are actively involved providing aptamer-based services? 
  • What is the evolving trend of publications focused on aptamer-based therapeutics and technologies?
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in this domain? 
  • Which companies are actively filing patents to drive innovation in this niche segment?
  • What are the different initiatives undertaken by start-up players for the development of aptamer-based technologies in the recent past?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of aptamers market and its likely evolution in the short to mid-long term. 

Chapter 3 provides a general overview of the aptamers. In addition, it features information on the historical timeline and evolution of SELEX, processes involved in the selection of aptamers. It also features an elaborate description of types of aptamers and need for aptamer modifications. Further, it highlights the various applications of aptamers and opportunities associated within the domain.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics, along with information on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers, L-RNA aptamers and peptide aptamers), location of headquarters, phase of development (discovery, pre-clinical, clinical and approved), line of treatment (1st and 2nd line of treatment), mechanism of action, route of administration (intravenous, intravitreal and subcutaneous), type of therapy (monotherapy and combinational therapy), therapeutic area (bleeding disorders, bone disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders and ophthalmological disorders) and target indication (geographic atrophy, macular degeneration, stroke, acute stroke, ischemic stroke, multiple myeloma, chronic lymphocytic leukemia, metastatic pancreatic cancer and others).

Chapter 5 provides a detailed overview of the current market landscape of players engaged in the development of aptamer-based technologies, based on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers and peptide aptamers), location of headquarters, status of development (concept, under development and commercialized), type of technology used (SELEX, NGS, ELISA and others), application area (research, diagnostic and therapeutic purposes), purpose of technology (Characterization, drug discovery, drug development, identification, biomarker discovery, assay, validation and others), type of analyte (serum, plasma, saliva and others), therapeutic area (autoimmune disorders, infectious disorders, neurodegenerative disorders, neurological disorders, antibiotic resistance, bone disorders, CNS disorders, genetic disorders, infectious diseases, nephrological disorders, oncological disorders, ophthalmological disorders, oral diseases and psychological disorders) and target indication (amyotrophic lateral sclerosis,  breast cancer,  colon cancer, dengue virus,  liver cancer,  prostate cancer, porcine reproductive and respiratory syndrome virus (PRRSv), mycoplasma hyopneumoniae,  stomach cancer and others).

Chapter 6 provides a detailed overview of the current market landscape of aptamer-based service providers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service provider (contract research organizations, contract manufacturing organizations and third-party service providers), scale of operation (small, medium and large scale), area of application (therapeutic, diagnostic and others), type of technology used (ELISA, NGS, SELEX and others), type of technology platform (computational and others), and types of analysis offered (discovery, screening, characterization, synthesis, modification and purification).

Chapter 7 provides an insightful competitiveness analysis of aptamer-based service providers, based on several relevant parameters, such as supplier strength (in terms of years of experience), portfolio strength (in terms of number of services offered) and portfolio diversity (based on scale of operation, area of application, technology used and types of analysis offered).

Chapter 8 provides an insightful competitiveness analysis of aptamer-based technologies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on type of aptamer, status of development, area of application, type of technology used and purpose of technology).

Chapter 9 provides an insightful product competitiveness analysis, benchmarking aptamer-based therapies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on phase of development, line of treatment, type of therapy, route of administration and target indication).

Chapter 10 features an analysis on the recent developments within the aptamers industry, highlighting information on several partnerships and collaborations that have been established in this domain, during the period 2016-2021. 

Chapter 11 features a detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in this domain, during the period 2016-2021.

Chapter 12 consists of an analysis of academic grants that have been awarded to various research institutes for projects focused on aptamers, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.

Chapter 13 provides a detailed review of close to 390 peer-reviewed, scientific articles related to research on aptamers, based on several parameters, such as year of publication, type of publication, and popular keywords. The chapter also provides information on the top journals, top institutes and top authors (in terms of number of articles published).

Chapter 14 consists of an analysis of patents related to aptamer-based therapies and technologies, filed / granted since 2016, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 15 provides a detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players and regional distribution of trials.

Chapter 16 provides an analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of technologies offered, type of aptamer, status of development, area of application, type of technology used and purpose of technology.

Chapter 17 includes elaborate profiles of prominent players (shortlisted based our proprietary scoring criteria) engaged in this domain. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key executives. It also includes details on their respective product portfolio, recent developments and an informed future outlook.

Chapter 18 includes elaborate profiles of prominent technologies (shortlisted based our proprietary scoring criteria) developed by players engaged in this domain. Each technology profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details on their respective technology portfolio, recent developments and an informed future outlook.

Chapter 19 presents and informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics, taking into account the target patient population in ongoing and planned clinical trials focused on aptamer-based therapies, sponsored by both industry and non-industry players.

Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of aptamers market, till 2032. In order to provide a detailed future outlook, our projections have been segmented across different segments on the basis of [A] application area (therapeutics, research and diagnostics), [B] type of aptamer (DNA, RNA and peptide), [C] target indications (geographic atrophy, macular degeneration, Von Willebrand diseases, hemophilia A), [D] route of administration (intravitreal, intravenous, subcutaneous), [E] scale of operation (clinical and commercial), [F] focus area (product development, product commercialization, technology integration, technology utilization and others), [G] company size (very small, small, mid-sized, large and very large) and [H] key geographical regions (North America, Europe, Asia-Pacific And Rest of the World).

Chapter 21 presents an insightful discussion on the views presented by various industry experts present across the globe, on YouTube. The summary of insights provided by each expert is discussed across focus area, current industry status / challenges and future outlook

Chapter 22 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the aptamers market.

Chapter 23 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 24 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Aptamers
3.2.1. Systematic Evolution of Ligands by Exponential Enrichment (SELEX)
3.3. Types of Aptamers
3.3.1. DNA Aptamers
3.3.2. RNA Aptamers
3.3.3. Peptide Aptamers
3.3.4. XNA Aptamers
3.4. Need for Aptamer Modifications
3.5. Advantages of Aptamers
3.6. Limitations of Aptamers
3.7. Applications of Aptamers
3.8. Future Anticipated Trends and Opportunities

4. MARKET OVERVIEW: THERAPEUTIC CANDIDATES
4.1. Chapter Overview
4.2. Aptamer-based Therapeutics: Market Landscape
4.2.1. Analysis by Type of Aptamer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Target Indication
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Type of Therapy

4.3. Aptamer-based Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Therapies

5. MARKET OVERVIEW: TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Aptamer-based Technologies: Market Landscape
5.2.1. Analysis by Type of Aptamer
5.2.2. Analysis by Status of Development
5.2.3. Analysis by Application Area
5.2.4. Analysis by Type of Technology Used
5.2.5. Analysis by Purpose of Technology
5.2.6. Analysis by Type of Analyte
5.2.7. Analysis by Therapeutic Area
5.2.8. Analysis by Target Indication
5.2.9. Analysis by Application Area, Purpose of Technology and Region

5.3. Aptamer-based Technologies: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Company Size and Location of Headquarters

6. MARKET OVERVIEW: SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Aptamer-based Service Providers: Market Landscape
6.2.1. Analysis by Type of Service Provider
6.2.2. Analysis by Scale of Operation
6.2.3. Analysis by Application Area
6.2.4. Analysis by Type of Technology Used
6.2.5. Analysis by Type of Technology Platform
6.2.6. Analysis by Types of Analysis Offered
6.2.7. Analysis by Type of Service Provider, Type of Analysis Offered and Region

6.3. Aptamer-based Service Providers: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Company Size and Location of Headquarters

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Aptamer-based Service Providers: Company Competitiveness Analysis
7.3.1. Very Small Companies (Peer Group 1)
7.3.2. Small Companies (Peer Group 2)
7.3.3. Mid-sized Companies (Peer Group 3)
7.3.4. Large Companies (Peer Group 4)
7.3.5. Very Large Companies (Peer Group 5)

8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Aptamer-based Technology Providers
8.3.1. Very Small Companies (Peer Group 1)
8.3.2. Small Companies (Peer Group 2)
8.3.3. Mid-sized Companies (Peer Group 3)
8.3.4. Large Companies (Peer Group 4)
8.3.5. Very Large Companies (Peer Group 5)

9. PRODUCT COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Aptamer-based Therapeutics
9.3.1. Very Small Companies (Peer Group 1)
9.3.2. Small Companies (Peer Group 2)
9.3.3. Mid-sized Companies (Peer Group 3)
9.3.4. Large Companies (Peer Group 4)
9.3.5. Very Large Companies (Peer Group 5)

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Aptamer Therapeutics, Technologies and Service Providers: List of Partnerships and Collaborations
10.1.1 Analysis by Year, 2016-2021
10.1.2. Analysis by Type of Partnership
10.1.3. Analysis by Year and Type of Partnership
10.1.4. Analysis by Type of Partner
10.1.5. Analysis by Year and Type of Partner
10.1.6. Analysis by Type of Partnership and Type of Partner
10.1.7. Analysis by Focus Area
10.1.8. Most Active Players: Analysis by Number of Partnerships
10.1.9. Analysis by Region (Continent-wise)
10.1.9.1 Intercontinental and Intracontinental Agreements
10.1.10. Analysis by Region (Country-wise)
10.1.9.1 Local and International Agreements

11. FUNDING AND INVESTMENTS
11.1. Aptamer Therapeutics, Technologies and Service Providers: List of Funding and Investments
11.1.1. Cumulative Analysis of Instances by Year, 2016–2021
11.1.2. Analysis of Instances by Type of Funding
11.1.3. Analysis of Instances by Year and Type of Funding, 2016–2021
11.1.4. Cumulative Analysis of Amount Invested by Year, 2016–2021
11.1.5. Analysis of Amount Invested by Type of Funding
11.1.6. Analysis of Type of Funding and Amount Invested by Year, 2016–2021
11.1.7. Analysis of Instances by Region
11.1.8. Analysis of Total Amount Invested by Region
11.1.9. Most Active Players: Analysis by Number of Instances
11.1.10. Most Active Players: Analysis by Amount Raised
11.1.11. Most Active Investors: Analysis by Number of Instances

12. GRANTS ANALYSIS
12.1. Aptamer Therapeutics, Technologies and Service Providers: List of Academic Grants
12.1.1. Cumulative Year-wise Trend of Gransts, 2016-2021
12.1.2. Analysis by Grant Amount
12.1.3. Analysis by Activity Codes
12.1.4. Analysis by Support Period
12.1.5. Analysis by Purpose of Grant
12.1.6. Analysis by Type of Grant
12.1.7. Analysis by Funding Institute and Support Period
12.1.8. Analysis by Type of Organization
12.1.9. Most Popular Recipient Organization: Analysis by Number of Instances
12.1.10. Most Popular Recipient Organization: Analysis by Amount Granted
12.1.11. Most Popular Recipient Organization: Distribution in US
12.1.12. Prominent Program Officers: Analysis by Number of Grants
12.1.13. Analysis by Study Section
12.1.14. Analysis by Most Popular Department
12.1.15. Word Cloud of Popular NIH Spending Categories

13. PUBLICATION ANALYSIS
13.1. Aptamer Therapeutics, Technologies and Service Providers: List of Publications
13.1.1. Analysis by Quarterly Trend of Publications (2021)
13.1.2. Analysis by Type of Publication
13.1.3. Analysis by Most Popular Journal
13.1.4. Analysis by Most Popular Author
13.1.5. Analysis by Most Popular Publisher
13.1.6. Analysis by Most Popular Copyright Holder
13.1.7. Analysis by Most Popular Keywords
13.1.8. Analysis by Affiliation
13.1.9. Analysis by Affiliation and Geography
13.1.10. Analysis by Funding Institutes

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Aptamer Therapeutics, Technologies and Service Providers: Patent Analysis
14.3.1. Analysis by Type of Patent
14.3.2. Analysis by Granted Patents
14.3.3. Analysis by Publication Year
14.3.4. Year-wise Trend of Filed Patent Applications
14.3.5. Analysis by Issuing Authority
14.3.6. Analysis by Patent Focus
14.3.7. Analysis by Patent Age
14.3.8. Analysis by CPC Symbols
14.3.9. Analysis by Type of Applicant
14.3.10. Leading Players: Analysis by Number of Patents

15. CLINICAL TRIAL ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Aptamer-based Therapeutics: List of Clinical Trials
15.3.1. Analysis by Trial Status
15.3.2. Analysis by Trial Registration Year
15.3.3. Analysis by Trial Status and Trial Registration Year
15.3.4. Analysis by Number of Patients Enrolled and Phase of Development
15.3.5. Analysis by Type of Sponsor
15.3.6. Analysis by Target Patient Group
15.3.7. Analysis by Study Type
15.3.8. Analysis by Type of Masking
15.3.9. Analysis by Type of Interventional Model
15.3.10. Analysis by Primary Purpose of Trial
15.3.11. Analysis of Enrolled Patient Population by Geography

16. START-UP HEALTH INDEXING
16.1. START-UP HEALTH INDEXING
16.2. Start-ups Focused on Aptamer-based Technology Providers
16.3. Methodology and Key Parameters
16.4.1 Analysis by Number of Technologies
16.2.2. Analysis by Type of Aptamer
16.2.3. Analysis by Status of Development
16.2.4. Analysis by Area of Application
16.2.5. Analysis by Type of Bioanalytical Technology Used
16.2.6. Analysis by Technology Application Area
16.2.7. Analysis by Patent Count
16.2.8. Start-ups Health Indexing: Roots Analysis Perspective

17. COMPANY PROFILES
17.1. Chapter Overview
17.2. Ajinomoto Bio-Pharma Services
17.2.1. Company Overview
17.2.2. Financial Information
17.2.3. Service Portfolio
17.2.4. Recent Developments and Future Outlook

17.3. BioSpring
17.3.1. Company Overview
17.3.2. Service Portfolio
17.3.3. Recent Developments and Future Outlook

17.4. CliniSciences
17.4.1. Company Overview
17.4.2. Service Portfolio
17.4.3. Recent Developments and Future Outlook

17.5. New England Biolabs
17.5.1. Company Overview
17.5.2. Product Portfolio
17.5.3. Recent Developments and Future Outlook

17.6. LGC Biosearch Technologies
17.6.1. Company Overview
17.6.2. Financial Information
17.6.3. Product Portfolio
17.6.4. Recent Developments and Future Outlook

17.7. Nitto Denko Avecia
17.7.1. Company Overview
17.7.2. Service Portfolio
17.7.3. Manufacturing Facilities and Capabilities
17.7.4. Recent Developments and Future Outlook

17.8. CMIC Group
17.8.1. Company Overview
17.8.2. Product Portfolio
17.8.3. Recent Developments and Future Outlook

18. TECHNOLOGY PROFILES
18.1. Chapter Overview
18.2. SomaLogic
18.2.1. Company Overview
18.2.2. Technology Overview
18.2.3. SomaScan
18.2.4. Recent Developments and Future Outlook

18.3. NOXXON Pharma
18.3.1. Company Overview
18.3.2. Technology Overview
18.3.3. Recent Developments and Future Outlook

18.4. RIBOMIC
18.4.1. Company Overview
18.4.2. Financial Information
18.4.3. Technology Overview
18.4.4. Recent Developments and Future Outlook

18.5. Halo-Bio RNAi Therapeutics
18.5.1. Company Overview
18.5.2. Technology Overview
18.5.3. Recent Developments and Future Outlook

18.6. NeuroNeuro
18.6.1. Company Overview
18.6.2. Technology Overview
18.6.3. Aptamarkers
18.6.4. Recent Developments and Future Outlook

19. DEMAND ANALYSIS
19.1. Chapter Overview
19.2. Scope and Methodology
19.3. Global Demand for Aptamers
19.4. Analysis by Scale of Operation
19.4.1. Clinical Demand for Aptamers
19.4.2. Commercial Demand for Aptamers
19.5. Analysis by Region
19.5.1. Demand for Aptamers in North America
19.5.2. Demand for Aptamers in Europe
19.5.3. Demand for Aptamers in Asia-Pacific

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Forecast Methodology
20.3. Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
20.4. Aptamer Therapeutics Market, 2022-2035

20.4.1. Aptamer Therapeutics Market: Analysis by Type of Aptamer, 2022-2035
20.4.1.1. Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
20.4.1.2. Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
20.4.1.3. Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035

20.4.2. Aptamer Therapeutics Market: Analysis by Target Indication, 2022-2035
20.4.2.1. Aptamer Therapeutics Market for Brain Cancer, 2022-2035
20.4.2.2. Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
20.4.2.3. Aptamer Therapeutics Market for Hemophilia A, 2022-2035
20.4.2.4. Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
20.4.2.5. Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
20.4.2.6. Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035

20.4.3. Aptamer Therapeutics Market: Analysis by Route of Administration, 2022-2035
20.4.3.1. Aptamer Therapeutics Market for Intravenous Route, 2022-2035
20.4.3.2. Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
20.4.3.3. Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035

20.4.4. Aptamer Therapeutics Market: Analysis by Geography, 2022-2035
20.4.4.1. Aptamer Therapeutics Market in North America, 2022-2035
20.4.4.2. Aptamer Therapeutics Market in Europe, 2022-2035
20.4.4.3. Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
20.4.4.4. Aptamer Therapeutics Market in Rest of the World, 2022-2035

20.4.5. Drug-wise Sales Forecast
20.4.5.1. Zimura (Iveric Bio)
20.4.5.1.1. Target Patient Population
20.4.5.1.2. Value Creation Analysis

20.4.5.2. NOX-A12 (NOXXON Pharma)
20.4.5.2.1. Target Patient Population
20.4.5.2.2. Value Creation Analysis

20.4.5.3. BT 200 (Guardian therapeutics)
20.4.5.3.1. Target Patient Population
20.4.5.3.2. Value Creation Analysis

20.4.5.4. BC007 (Berlin Cures)
20.4.5.4.1. Target Patient Population
20.4.5.4.2. Value Creation Analysis

20.5. Aptamer Technologies Market, 2022-2035
20.5.1. Aptamer Technologies Market: Analysis by Focus Area, 2022-2035
20.5.1.1. Aptamer Therapeutics Market for Product Development Initiatives, 2022-2035
20.5.1.2. Aptamer Therapeutics Market for Product Commercialization Initiatives, 2022-2035
20.5.1.3. Aptamer Therapeutics Market for Technology Integration Initiatives, 2022-2035
20.5.1.4. Aptamer Therapeutics Market for Technology Utilization Initiatives, 2022-2035
20.5.1.5. Aptamer Therapeutics Market for Other Initiatives, 2022-2035

20.5.2. Aptamer Technologies Market: Analysis by Company Size, 2022-2035
20.5.1.1. Aptamer Therapeutics Market for Very Small Companies, 2022-2035
20.5.1.2. Aptamer Therapeutics Market for Small Companies, 2022-2035
20.5.1.3. Aptamer Therapeutics Market for Mid-sized Companies, 2022-2035
20.5.1.4. Aptamer Therapeutics Market for Large Companies, 2022-2035
20.5.1.5. Aptamer Therapeutics Market for Very Large Companies, 2022-2035

20.5.3. Aptamer Technologies Market: Analysis by Geography, 2022-2035
20.5.3.1. Aptamer Technologies Market in North America, 2022-2035
20.5.3.2. Aptamer Technologies Market in Europe, 2022-2035
20.5.3.3. Aptamer Technologies Market in Asia-Pacific, 2022-2035

20.6. Aptamer Services Market, 2022-2035
20.6.1. Aptamer Services Market: Analysis by Scale of Operation, 2022-2035
20.6.1.1. Aptamer Services Market for Small Scale Operations, 2022-2035
20.6.1.2. Aptamer Services Market for Medium-Scale Operations, 2022-2035
20.6.1.3. Aptamer Services Market for Large Scale Operations, 2022-2035

20.6.2. Aptamer Technologies Market: Analysis by Geography, 2022-2035
20.6.2.1. Aptamer Technologies Market in North America, 2022-2035
20.6.2.2. Aptamer Technologies Market in Europe, 2022-2035
20.6.2.3. Aptamer Technologies Market in Asia-Pacific, 2022-2035

21. CONCLUSION

22. APPENDIX I: TABULATED DATA

23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investments
Figure 2.4 Executive Summary: Grants Analysis
Figure 2.5 Executive Summary: Publication Analysis
Figure 2.6 Executive Summary: Patent Analysis
Figure 2.7 Executive Summary: Clinical Trial Analysis
Figure 2.8 Executive Summary: Demand Analysis
Figure 2.9 Executive Summary: Market Forecast
Figure 3.1 Evolution of SELEX
Figure 3.2 Process of Synthesizing DNA Aptamers
Figure 3.3 Process of Synthesizing RNA Aptamers
Figure 3.4 Types of Aptamer Modifications
Figure 3.5 Applications of Aptamers
Figure 4.1 Aptamer-based Therapeutics: Distribution by Type of Aptamer
Figure 4.2 Aptamer-based Therapeutics: Distribution by Phase of Development
Figure 4.3 Aptamer-based Therapeutics: Distribution by Line of Treatment
Figure 4.4 Aptamer-based Therapeutics: Distribution by Route of Administration
Figure 4.5 Aptamer-based Therapeutics: Distribution by Mechanism of Action
Figure 4.6 Aptamer-based Therapeutics: Distribution by Target Indication
Figure 4.7 Aptamer-based Therapeutics: Distribution by Therapeutic Area
Figure 4.8 Aptamer-based Therapeutics: Distribution by Type of Therapy
Figure 4.9 Aptamer-based Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10 Aptamer-based Therapeutics Developers: Distribution by Company Size
Figure 4.11 Aptamer-based Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.12 Aptamer-based Therapeutics Developers: Distribution by Company Size and Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Therapies
Figure 5.1 Aptamer-based Technologies: Distribution by Type of Aptamer
Figure 5.2 Aptamer-based Technologies: Distribution by Status of Development
Figure 5.3 Aptamer-based Technologies: Distribution by Application Area
Figure 5.4 Aptamer-based Technologies: Distribution by Type of Technology Used
Figure 5.5 Aptamer-based Technologies: Distribution by Purpose of Technology
Figure 5.6 Aptamer-based Technologies: Distribution by Type of Analyte
Figure 5.7 Aptamer-based Technologies: Distribution by Therapeutic Area
Figure 5.8 Aptamer-based Technologies: Distribution by Target Indication
Figure 5.9 Aptamer-based Technologies: Distribution by Application Area, Purpose of Technology and Region
Figure 5.9 Aptamer-based Technology Providers Distribution by Year of Establishment
Figure 5.10 Aptamer-based Technology Providers: Distribution by Company Size
Figure 5.11 Aptamer-based Technology Providers: Distribution by Location of Headquarters
Figure 5.12 Aptamer-based Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 6.1 Aptamer-based Service Providers: Distribution by Type of Service Provider
Figure 6.2 Aptamer-based Service Providers: Distribution by Scale of Operation
Figure 6.3 Aptamer-based Service Providers: Distribution by Application Area
Figure 6.4 Aptamer-based Service Providers: Distribution by Type of Technology Used
Figure 6.5 Aptamer-based Service Providers: Distribution by Type of Technology Platform
Figure 6.6 Aptamer-based Service Providers: Distribution by Types of Analysis Offered
Figure 6.7 Aptamer-based Service Providers: Distribution by Type of Service Provider, Type of Analysis Offered and Region
Figure 6.8 Aptamer-based Service Providers: Distribution by Year of Establishment
Figure 6.9 Aptamer-based Service Providers: Distribution by Company Size
Figure 6.10 Aptamer-based Service Providers: Distribution by Location of Headquarters
Figure 6.11 Aptamer-based Service Providers: Distribution by Company Size and Location of Headquarters
Figure 7.1 Company Competitiveness Analysis: Very Small Companies (Peer Group 1)
Figure 7.2 Company Competitiveness Analysis: Small Companies (Peer Group 2)
Figure 7.3 Company Competitiveness Analysis: Mid-sized Companies (Peer Group 3)
Figure 7.4 Company Competitiveness Analysis: Large Companies (Peer Group 4)
Figure 7.5 Company Competitiveness Analysis: Very Large Companies (Peer Group 5)
Figure 8.1 Technology Competitiveness Analysis: Very Small Companies (Peer Group 1)
Figure 8.2 Technology Competitiveness Analysis: Small Companies (Peer Group 2)
Figure 8.3 Technology Competitiveness Analysis: Mid-sized Companies (Peer Group 3)
Figure 8.4 Technology Competitiveness Analysis: Large Companies (Peer Group 4)
Figure 8.5 Technology Competitiveness Analysis: Very Large Companies (Peer Group 5)
Figure 9.1 Product Competitiveness Analysis: Very Small Companies (Peer Group 1)
Figure 9.2 Product Competitiveness Analysis: Small Companies (Peer Group 2)
Figure 9.3 Product Competitiveness Analysis: Mid-sized Companies (Peer Group 3)
Figure 9.4 Product Competitiveness Analysis: Large Companies (Peer Group 4)
Figure 9.5 Product Competitiveness Analysis: Very Large Companies (Peer Group 5)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Distribution, 2016-2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.5 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partnership and Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Focus Area
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.11 Partnerships and Collaborations: Distribution by Region (Country-wise)
Figure 10.12 Partnerships and Collaborations: Local and International Agreements
Figure 11.1 Funding and Investments: Cumulative Distribution of Instances by Year, 2016–2021
Figure 11.2 Funding and Investments: Distribution of Instances by Type of Funding
Figure 11.3 Funding and Investments: Distribution of Instances by Year and Type of Funding, 2016–2021
Figure 11.4 Funding and Investments: Cumulative Distribution of Amount Invested by Year, 2016–2021
Figure 11.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 11.6 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding, 2016–2021
Figure 11.7 Funding and Investments: Distribution of Instances by Region
Figure 11.8 Funding and Investments: Distribution of Total Amount Invested by Region
Figure 11.9 Most Active Players: Distribution by Number of Instances
Figure 11.10 Most Active Players: Distribution by Amount Raised
Figure 11.11 Most Active Investors: Distribution by Number of Instances
Figure 12.1 Grant Analysis: Cumulative Year-wise Trend, 2016-2021
Figure 12.2 Grant Analysis: Distribution by Grant Amount
Figure 12.3 Grant Analysis: Distribution by Activity Code
Figure 12.4 Grant Analysis: Distribution by Support Period
Figure 12.5 Grant Analysis: Distribution by Purpose of Grant
Figure 12.6 Grant Analysis: Distribution by Type of Grant
Figure 12.7 Grant Analysis: Distribution by Funding Institute and Support Period
Figure 12.8 Grant Analysis: Distribution by Type of Organization
Figure 12.9 Most Popular Recipient Organization: Distribution by Number of Instances
Figure 12.10 Most Popular Recipient Organization: Distribution by Amount Granted
Figure 12.11 Most Popular Recipient Organization: Distribution in US
Figure 12.12 Prominent Program Officers: Distribution by Number of Grants
Figure 12.13 Academic Grant Analysis: Distribution by Study Section
Figure 12.14 Academic Grant Analysis: Distribution by Most Popular Department
Figure 12.15 Academic Grant Analysis: Distribution of Popular NIH Spending Categories
Figure 13.1 Publication Analysis: Quarterly Trend of Publications (2021)
Figure 13.2 Publication Analysis: Distribution by Type of Publication
Figure 13.3 Most Prominent Journals: Distribution by Number of Publications
Figure 13.4 Most Prominent Authors: Distribution by Number of Publications
Figure 13.5 Most Popular Publishers: Distribution by Number of Publications
Figure 13.6 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 13.7 Most Popular Keywords: Distribution by Number of Publications
Figure 13.8 Publication Analysis: Distribution by Affiliation
Figure 13.9 Publication Analysis: Distribution by Affiliation and Geography
Figure 13.10 Publication Analysis: Distribution by Funding Institute
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Distribution by Granted Patents
Figure 14.3 Patent Analysis: Distribution by Publication Year
Figure 14.4 Patent Analysis: Year-wise Trend of Filed Patent Applications
Figure 14.5 Patent Analysis: Distribution by Issuing Authority
Figure 14.6 Patent Analysis: Distribution by Focus Area
Figure 14.7 Patent Analysis: Distribution by Patent Age
Figure 14.8 Patent Analysis: Distribution by CPC Symbols
Figure 14.9 Patent Analysis: Distribution by Type of Applicant
Figure 14.10 Leading Players: Distribution by Number of Patents
Figure 15.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Status and Trial Registration Year
Figure 15.4 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Phase of Development
Figure 15.5 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 15.6 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 15.7 Clinical Trial Analysis: Distribution by Study Design
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Masking
Figure 15.9 Clinical Trial Analysis: Distribution by Type of Interventional Model
Figure 15.10 Clinical Trial Analysis: Distribution by Primary Purpose of Trial
Figure 15.11 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 16.1 Start-up Health Indexing: Distribution by Number of Technologies
Figure 16.2 Start-up Health Indexing: Distribution by Type of Aptamer
Figure 16.3 Start-up Health Indexing: Distribution by Status of Development
Figure 16.4 Start-up Health Indexing: Distribution by Area of Application
Figure 16.5 Start-up Health Indexing: Distribution by Type of Bioanalytical Technology Used
Figure 16.6 Start-up Health Indexing: Distribution by Technology Application Area
Figure 16.7 Start-up Health Indexing: Distribution by Patent Count
Figure 16.8 Start-up Health Indexing: Roots Analysis Perspective
Figure 19.1 Demand Analysis: Global Demand for Aptamers
Figure 19.2 Demand Analysis: Distribution by Scale of Operation
Figure 19.3 Demand Analysis: Clinical Demand for Aptamers
Figure 19.4 Demand Analysis: Commercial Demand for Aptamers
Figure 19.5 Demand Analysis: Distribution by Region
Figure 19.6 Demand Analysis: Demand for Aptamers in North America
Figure 19.7 Demand Analysis: Demand for Aptamers in Europe
Figure 19.8 Demand Analysis: Demand for Aptamers in Asia-Pacific
Figure 20.1 Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
Figure 20.2 Aptamer Therapeutics Market, 2022-2035
Figure 20.3 Aptamer Therapeutics Market: Distribution by Type of Aptamer, 2022-2035
Figure 20.4 Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
Figure 20.5 Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
Figure 20.6 Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035
Figure 20.7 Aptamer Therapeutics Market: Distribution by Target Indication, 2022-2035
Figure 20.8 Aptamer Therapeutics Market for Brain Cancer, 2022-2035
Figure 20.9 Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
Figure 20.10 Aptamer Therapeutics Market for Hemophilia A, 2022-2035
Figure 20.11 Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
Figure 20.12 Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
Figure 20.13 Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035
Figure 20.14 Aptamer Therapeutics Market: Distribution by Route of Administration, 2022-2035
Figure 20.15 Aptamer Therapeutics Market for Intravenous Route, 2022-2035
Figure 20.16 Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
Figure 20.17 Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035
Figure 20.18 Aptamer Therapeutics Market: Distribution by Geography, 2022-2035
Figure 20.19 Aptamer Therapeutics Market in North America, 2022-2035
Figure 20.20 Aptamer Therapeutics Market in Europe, 2022-2035
Figure 20.21 Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
Figure 20.22 Aptamer Therapeutics Market in Rest of the World, 2022-2035
Figure 20.23 Aptamer Technologies Market, 2022-2035
Figure 20.24 Aptamer Technologies Market: Distribution by Focus Area, 2022-2035
Figure 20.25 Aptamer Technologies Market for Product Development Initiatives, 2022-2035
Figure 20.26 Aptamer Technologies Market for Product Commercialization Initiatives, 2022-2035
Figure 20.27 Aptamer Technologies Market for Technology Integration Initiatives, 2022-2035
Figure 20.28 Aptamer Technologies Market for Technology Utilization Initiatives, 2022-2035
Figure 20.29 Aptamer Technologies Market for Other Initiatives, 2022-2035
Figure 20.30 Aptamer Technologies Market: Distribution by Company Size, 2022-2035
Figure 20.31 Aptamer Technologies Market for Very Small Companies, 2022-2035
Figure 20.32 Aptamer Technologies Market for Small Companies, 2022-2035
Figure 20.33 Aptamer Technologies Market for Mid-sized Companies, 2022-2035
Figure 20.34 Aptamer Technologies Market for Large Companies, 2022-2035
Figure 20.35 Aptamer Technologies Market for Very Large Companies, 2022-2035
Figure 20.36 Aptamer Technologies Market: Distribution by Geography, 2022-2035
Figure 20.37 Aptamer Technologies Market in North America, 2022-2035
Figure 20.38 Aptamer Technologies Market in Europe, 2022-2035
Figure 20.39 Aptamer Technologies Market in Asia-Pacific, 2022-2035
Figure 20.40 Aptamer Services Market, 2022-2035
Figure 20.41 Aptamer Services Market: Distribution by Scale of Operation, 2022-2035
Figure 20.42 Aptamer Services Market for Small Scale Operations, 2022-2035
Figure 20.43 Aptamer Services Market for Medium-Scale Operations, 2022-2035
Figure 20.44 Aptamer Services Market for Large Scale Operations, 2022-2035
Figure 20.45 Aptamer Services Market: Distribution by Geography, 2022-2035
Figure 20.46 Aptamer Services Market in North America, 2022-2035
Figure 20.47 Aptamer Services Market in Europe, 2022-2035
Figure 20.48 Aptamer Services Market in Asia-Pacific, 2022-2035
Figure 21.1 Concluding Remarks: Overall Market Landscape
Figure 21.2 Concluding Remarks: Partnerships and Collaborations
Figure 21.3 Concluding Remarks: Funding and Investments
Figure 21.4 Concluding Remarks: Grants Analysis
Figure 21.5 Concluding Remarks: Publication Analysis
Figure 21.6 Concluding Remarks: Patent Analysis
Figure 21.7 Concluding Remarks: Clinical Trial Analysis
Figure 21.8 Concluding Remarks: Demand Analysis
Figure 21.9 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Key Characteristics: Aptamers versus Antibodies
Table 3.2 Comparison of DNA, RNA and Peptide Aptamers
Table 4.1 Aptamer-based Therapeutics: Information on Phase of Development, Type of Aptamer, Target Indication and Therapeutic Area
Table 4.2 Aptamer-based Therapeutics: Information on Line of Treatment, Route of Administration, Mechanism of Action and Type of Therapy
Table 4.3 List of Aptamer-based Therapeutic Developers
Table 5.1 Aptamer-based Technologies: Information on Status of Development and Type of Aptamer
Table 5.2 Aptamer-based Technologies: Information on Application Area, Type of Technology
Table 5.3 Aptamer-based Technologies: Information on Purpose of Technology and Type of Analyte Needed
Table 5.4 List of Aptamer-based Technology Developers
Table 6.1 Aptamer-based Technology Providers: Information on Type of Service Provider, Scale of Operation and Application Area
Table 6.2 Aptamer-based Technology Providers: Information on Technology Used for Analysis and Analysis Offered
Table 6.3 List of Aptamer-based Service Providers
Table 10.1 Aptamer Therapeutics, Technologies and Service Providers: List of Partnerships and Collaborations
Table 11.1 Aptamer Therapeutics, Technologies and Service Providers: List of Funding and Investments
Table 12.1 Aptamer Therapeutics, Technologies and Service Providers: List of Academic Grants
Table 13.1 Aptamer Therapeutics, Technologies and Service Providers: List of Publications
Table 15.3 Aptamer-based Therapeutics: List of Clinical Trials
Table 17.1 Ajinomoto Bio-Pharma Services: Key Highlights
Table 17.2 Ajinomoto Bio-Pharma Services: Service Portfolio
Table 17.3 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 17.4 BioSpring: Key Highlights
Table 17.5 BioSpring: Service Portfolio
Table 17.6 CliniSciences: Key Highlights
Table 17.7 New England Biolabs: Key Highlights
Table 17.8 New England Biolabs: Product Portfolio
Table 17.9 New England Biolabs: Recent Developments and Future Outlook
Table 17.10 Biosearch Technologies: Key Highlights
Table 17.11 Biosearch Technologies: Service Portfolio
Table 17.12 Biosearch Technologies: Manufacturing Facilities and Capabilities
Table 17.13 Biosearch Technologies: Recent Developments and Future Outlook
Table 17.14 Nitto Denko Avecia: Key Highlights
Table 17.15 Nitto Denko Avecia: Recent Developments and Future Outlook
Table 17.16 CMIC Group: Key Highlights
Table 17.17 CMIC Group: Recent Developments and Future Outlook
Table 18.1 SomaLogic: Recent Developments and Future Outlook
Table 18.2 NOXXON Pharma: Recent Developments and Future Outlook
Table 18.3 RIBOMIC: Recent Developments and Future Outlook
Table 21.1 Concluding Remarks: Overall Market Landscape
Table 21.2 Concluding Remarks: Partnerships and Collaborations
Table 21.3 Concluding Remarks: Funding and Investments
Table 21.4 Concluding Remarks: Grants Analysis
Table 21.5 Concluding Remarks: Publication Analysis
Table 21.6 Concluding Remarks: Patent Analysis
Table 21.7 Concluding Remarks: Clinical Trial Analysis
Table 21.8 Concluding Remarks: Demand Analysis
Table 21.9 Concluding Remarks: Market Forecast
Table 22.1 Aptamer-based Therapeutics: Distribution by Type of Aptamer
Table 22.1 Aptamer-based Therapeutics: Distribution by Type of Aptamer
Table 22.2 Aptamer-based Therapeutics: Distribution by Phase of Development
Table 22.3 Aptamer-based Therapeutics: Distribution by Line of Treatment
Table 22.4 Aptamer-based Therapeutics: Distribution by Route of Administration
Table 22.5 Aptamer-based Therapeutics: Distribution by Mechanism of Action
Table 22.6 Aptamer-based Therapeutics: Distribution by Target Indication
Table 22.7 Aptamer-based Therapeutics: Distribution by Therapeutic Area
Table 22.8 Aptamer-based Therapeutics: Distribution by Type of Therapy
Table 22.9 Aptamer-based Therapeutics Developers: Distribution by Year of Establishment
Table 22.10 Aptamer-based Therapeutics Developers: Distribution by Company Size
Table 22.11 Aptamer-based Therapeutics Developers: Distribution by Location of Headquarters
Table 22.12 Aptamer-based Therapeutics Developers: Distribution by Company Size and Location of Headquarters
Table 22.13 Most Active Players: Distribution by Number of Therapies
Table 22.14 Aptamer-based Technologies: Distribution by Type of Aptamer
Table 22.15 Aptamer-based Technologies: Distribution by Status of Development
Table 22.16 Aptamer-based Technologies: Distribution by Application Area
Table 22.17 Aptamer-based Technologies: Distribution by Type of Technology Used
Table 22.18 Aptamer-based Technologies: Distribution by Purpose of Technology
Table 22.19 Aptamer-based Technologies: Distribution by Type of Analyte
Table 22.20 Aptamer-based Technologies: Distribution by Therapeutic Area
Table 22.21 Aptamer-based Technologies: Distribution by Target Indication
Table 22.22 Aptamer-based Technologies: Distribution by Application Area, Purpose of Technology and Region
Table 22.23 Aptamer-based Technology Providers Distribution by Year of Establishment
Table 22.24 Aptamer-based Technology Providers: Distribution by Company Size
Table 22.25 Aptamer-based Technology Providers: Distribution by Location of Headquarters
Table 22.26 Aptamer-based Technology Providers: Distribution by Company Size and Location of Headquarters
Table 22.27 Aptamer-based Service Providers: Distribution by Type of Service Provider
Table 22.28 Aptamer-based Service Providers: Distribution by Scale of Operation
Table 22.29 Aptamer-based Service Providers: Distribution by Application Area
Table 22.30 Aptamer-based Service Providers: Distribution by Type of Technology Used
Table 22.31 Aptamer-based Service Providers: Distribution by Type of Technology Platform
Table 22.32 Aptamer-based Service Providers: Distribution by Types of Analysis Offered
Table 22.33 Aptamer-based Service Providers: Distribution by Type of Service Provider, Type of Analysis Offered and Region
Table 22.34 Aptamer-based Service Providers: Distribution by Year of Establishment
Table 22.35 Aptamer-based Service Providers: Distribution by Company Size
Table 22.36 Aptamer-based Service Providers: Distribution by Location of Headquarters
Table 22.37 Aptamer-based Service Providers: Distribution by Company Size and Location of Headquarters
Table 22.38 Partnerships and Collaborations: Cumulative Year-wise Distribution, 2016-2021
Table 22.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 22.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 22.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 22.42 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 22.43 Partnerships and Collaborations: Distribution by Type of Partnership and Partner
Table 22.44 Partnerships and Collaborations: Distribution by Focus Area
Table 22.45 Most Active Players: Distribution by Number of Partnerships
Table 22.46 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Table 22.47 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 22.48 Partnerships and Collaborations: Distribution by Region (Country-wise)
Table 22.49 Partnerships and Collaborations: Local and International Agreements
 
Table 22.50 Funding and Investments: Cumulative Distribution of Instances by Year, 2016–2021
Table 22.51 Funding and Investments: Distribution of Instances by Type of Funding
Table 22.52 Funding and Investments: Distribution of Instances by Year and Type of Funding, 2016–2021
Table 22.53 Funding and Investments: Cumulative Distribution of Amount Invested by Year, 2016–2021
Table 22.54 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 22.55 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding, 2016–2021
Table 22.56 Funding and Investments: Distribution of Instances by Region
Table 22.57 Funding and Investments: Distribution of Total Amount Invested by Region
Table 22.58 Most Active Players: Distribution by Number of Instances
Table 22.59 Most Active Players: Distribution by Amount Raised
Table 22.60 Most Active Investors: Distribution by Number of Instances
Table 22.61 Grant Analysis: Cumulative Year-wise Trend, 2016-2021
Table 22.62 Grant Analysis: Distribution by Grant Amount
Table 22.63 Grant Analysis: Distribution by Activity Code
Table 22.64 Grant Analysis: Distribution by Support Period
Table 22.65 Grant Analysis: Distribution by Purpose of Grant
Table 22.66 Grant Analysis: Distribution by Type of Grant
Table 22.67 Grant Analysis: Distribution by Funding Institute and Support Period
Table 22.68 Grant Analysis: Distribution by Type of Organization
Table 22.69 Most Popular Recipient Organization: Distribution by Number of Instances
Table 22.70 Most Popular Recipient Organization: Distribution by Amount Granted
Table 22.71 Most Popular Recipient Organization: Distribution in US
Table 22.72 Prominent Program Officers: Distribution by Number of Grants
Table 22.73 Academic Grant Analysis: Distribution by Study Section
Table 22.74 Academic Grant Analysis: Distribution by Most Popular Department
Table 22.75 Publication Analysis: Quarterly Trend of Publications (2021)
Table 22.76 Publication Analysis: Distribution by Type of Publication
Table 22.77 Most Prominent Journals: Distribution by Number of Publications
Table 22.78 Most Prominent Authors: Distribution by Number of Publications
Table 22.79 Most Popular Publishers: Distribution by Number of Publications
Table 22.80 Most Popular Copyright Holders: Distribution by Number of Publications
Table 22.81 Most Popular Keywords: Distribution by Number of Publications
Table 22.82 Publication Analysis: Distribution by Affiliation
Table 22.83 Publication Analysis: Distribution by Affiliation and Geography
Table 22.84 Publication Analysis: Distribution by Funding Institute
Table 22.85 Patent Analysis: Distribution by Type of Patent
Table 22.86 Patent Analysis: Distribution by Granted Patents
Table 22.87 Patent Analysis: Distribution by Publication Year
Table 22.88 Patent Analysis: Year-wise Trend of Filed Patent Applications
Table 22.89 Patent Analysis: Distribution by Issuing Authority
Table 22.90 Patent Analysis: Distribution by Patent Focus Area
Table 22.91 Patent Analysis: Distribution by Patent Age
Table 22.92 Patent Analysis: Distribution by CPC Symbols
Table 22.93 Patent Analysis: Distribution by Type of Applicant
Table 22.94 Leading Players: Distribution by Number of Patents
Table 22.95 Clinical Trial Analysis: Distribution by Trial Status
Table 22.96 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 22.97 Clinical Trial Analysis: Distribution by Trial Status and Trial Registration Year
Table 22.98 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Phase of Development
Table 22.99 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 22.100 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 22.101 Clinical Trial Analysis: Distribution by Study Design
Table 22.102 Clinical Trial Analysis: Distribution by Type of Masking
Table 22.103 Clinical Trial Analysis: Distribution by Type of Interventional Model
Table 22.104 Clinical Trial Analysis: Distribution by Primary Purpose of Trial
Table 22.105 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 22.106 Start-up Health Indexing: Distribution by Number of Technologies
Table 22.107 Start-up Health Indexing: Distribution by Type of Aptamer
Table 22.108 Start-up Health Indexing: Distribution by Status of Development
Table 22.109 Start-up Health Indexing: Distribution by Area of Application
Table 22.110 Start-up Health Indexing: Distribution by Type of Bioanalytical Technology Used
Table 22.111 Start-up Health Indexing: Distribution by Technology Application Area
Table 22.112 Start-up Health Indexing: Distribution by Patent Count
Table 22.113 Start-up Health Indexing: Roots Analysis Perspective
Table 22.114 Demand Analysis: Global Demand for Aptamers
Table 22.115 Demand Analysis: Distribution by Scale of Operation
Table 22.116 Demand Analysis: Clinical Demand for Aptamers
Table 22.117 Demand Analysis: Commercial Demand for Aptamers
Table 22.118 Demand Analysis: Distribution by Region
Table 22.119 Demand Analysis: Demand for Aptamers in North America
Table 22.120 Demand Analysis: Demand for Aptamers in Europe
Table 22.121 Demand Analysis: Demand for Aptamers in Asia-Pacific
Table 22.122 Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
Table 22.123 Aptamer Therapeutics Market, 2022-2035
Table 22.124 Aptamer Therapeutics Market: Distribution by Type of Aptamer, 2022-2035
Table 22.125 Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
Table 22.126 Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
Table 22.127 Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035
Table 22.128 Aptamer Therapeutics Market: Distribution by Target Indication, 2022-2035
Table 22.129 Aptamer Therapeutics Market for Brain Cancer, 2022-2035
Table 22.130 Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
Table 22.131 Aptamer Therapeutics Market for Hemophilia A, 2022-2035
Table 22.132 Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
Table 22.133 Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
Table 22.134 Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035
Table 22.135 Aptamer Therapeutics Market: Distribution by Route of Administration, 2022-2035
Table 22.136 Aptamer Therapeutics Market for Intravenous Route, 2022-2035
Table 22.137 Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
Table 22.138 Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035
Table 22.139 Aptamer Therapeutics Market: Distribution by Geography, 2022-2035
Table 22.140 Aptamer Therapeutics Market in North America, 2022-2035
Table 22.141 Aptamer Therapeutics Market in Europe, 2022-2035
Table 22.142 Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
Table 22.143 Aptamer Therapeutics Market in Rest of the World, 2022-2035
Table 22.144 Aptamer Technologies Market, 2022-2035
Table 22.145 Aptamer Technologies Market: Distribution by Focus Area, 2022-2035
Table 22.146 Aptamer Technologies Market for Product Development Initiatives, 2022-2035
Table 22.147 Aptamer Technologies Market for Product Commercialization Initiatives, 2022-2035
Table 22.148 Aptamer Technologies Market for Technology Integration Initiatives, 2022-2035
Table 22.149 Aptamer Technologies Market for Technology Utilization Initiatives, 2022-2035
Table 22.150 Aptamer Technologies Market for Other Initiatives, 2022-2035
Table 22.151 Aptamer Technologies Market: Distribution by Company Size, 2022-2035
Table 22.152 Aptamer Therapeutics Market for Very Small Companies, 2022-2035
Table 22.153 Aptamer Technologies Market for Small Companies, 2022-2035
Table 22.154 Aptamer Technologies Market for Mid-sized Companies, 2022-2035
Table 22.155 Aptamer Technologies Market for Large Companies, 2022-2035
Table 22.156 Aptamer Technologies Market for Very Large Companies, 2022-2035
Table 22.157 Aptamer Technologies Market: Distribution by Geography, 2022-2035
Table 22.158 Aptamer Technologies Market in North America, 2022-2035
Table 22.159 Aptamer Technologies Market in Europe, 2022-2035
Table 22.160 Aptamer Technologies Market in Asia-Pacific, 2022-2035
Table 22.161 Aptamer Services Market, 2022-2035
Table 22.162 Aptamer Services Market: Distribution by Scale of Operation, 2022-2035
Table 22.163 Aptamer Services Market for Small Scale Operations, 2022-2035
Table 22.164 Aptamer Services Market for Medium-Scale Operations, 2022-2035
Table 22.165 Aptamer Services Market for Large Scale Operations, 2022-2035
Table 22.166 Aptamer Services Market: Distribution by Geography, 2022-2035
Table 22.167 Aptamer Services Market in North America, 2022-2035
Table 22.168 Aptamer Services Market in Europe, 2022-2035
Table 22.169 Aptamer Services Market in Asia-Pacific, 2022-2035

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 2bind
  2. Accelero ® Bioanalytics  
  3. Achiko
  4. Acuitas Capital
  5. Admera Health
  6. Aju IB
  7. Allergan
  8. Amgen
  9. ASKA Pharmaceutical
  10. AstraZeneca
  11. blueconic
  12. Casdin Capital
  13. deCODE genetics (A Subsidiary of Amgen)
  14. DeepVerge
  15. Drive Therapeutics
  16. EIT Health
  17. Engineering and Physical Sciences Research Council (EPSRC)
  18. Epsilon Molecular Engineering
  19. Eurofins Genomics
  20. Eurogentec
  21. EVEC
  22. Eyetech Pharmaceuticals    (Acquired by Valeant Pharmaceuticals)
  23. Facible Biodiagnostics
  24. Farallon Capital Management
  25. Foresite Capital
  26. G. N. Tech Venture Investment
  27. GC Pharma
  28. Gene Link
  29. Genomictree
  30. Giner
  31. GlyTech
  32. GNS Healthcare
  33. Granzer Regulatory Consulting and Services
  34. Guardian Therapeutics
  35. Halo-Bio RNAi Therapeutics
  36. Hanlim Pharmaceutical
  37. Harvard University
  38. HB Investment
  39. Healios
  40. Horizon Discovery
  41. IBA Lifesciences
  42. iCarbonX
  43. ID Ventures
  44. Imperial College London
  45. Inception 4    (Acquired by IVERIC bio)
  46. Insight Partners
  47. Institute of Hematology and Transfusion Medicine
  48. Integrated DNA Technologies
  49. Intermountain Ventures
  50. Interoligo
  51. IVERIC bio
  52. Iwon Medical Foundation
  53. Ixaka
  54. Janssen
  55. Janus Henderson Investors
  56. Japan Agency for Medical Research and Development (AMED)
  57. Jena Bioscience
  58. Juntendo University School of Medicine
  59. Keio University School of Medicine
  60. King’s College London
  61. Kiwoom Investment
  62. Korea Investment Partners
  63. Kreos Capital
  64. LC Sciences
  65. Leeds Centre for Personalised Medicine and Health
  66. LGC
  67. LinkBio
  68. Logos Capital
  69. Lucerna
  70. Madryn Asset Management
  71. Maravai LifeSciences
  72. Maruho
  73. Masaryk University
  74. Massachusetts General Hospital
  75. Medical Innovation Ventures (Mediven®)
  76. Medical University of Vienna
  77. MeiraGTx
  78. Meneldor
  79. Merck
  80. Metabion
  81. Millennium Management
  82. Ministry of Science and Innovation (Spain)
  83. Mint Diagnostics
  84. Mizuho Capital
  85. Mologic
  86. MultiplexDX
  87. nal von minden
  88. Nan Fung Life Sciences
  89. NanoMosaic
  90. National Cancer Center
  91. National Center for Tumor Diseases (NCT)
  92. National Institutes of General Medical Sciences (NIGMS)
  93. National Institutes of Health
  94. NEC
  95. NEC Solution Innovators
  96. Nencki Institute of Experimental Biology
  97. NeoNeuro
  98. NeoVentures
  99. NES Biotechnology
  100. NeuraMedy
  101. New England Biolabs
  102. New York Stem Cell Foundation Research Institute (NYSCF)
  103. Nexmos
  104. Nitto Avecia
  105. NOVAPTECH
  106. Novartis
  107. Novo Nordisk
  108. NOXXON Pharma
  109. NVIGEN
  110. Nyenburgh Investment Partners (NYIP)
  111. Oak BioSciences
  112. Osaka University
  113. Otsuka Chemical
  114. Otsuka Pharmaceutical
  115. Oxford University
  116. PCL    Health
  117. Pecic Lab
  118. Peking Union Medical College
  119. PerkinElmer
  120. Pfizer
  121. PINOTBIO
  122. ProAxsis
  123. Profacgen
  124. Proteovista
  125. Pura Vida Investments
  126. Pure Biologics
  127. Qualigen Therapeutics
  128. Quimigen
  129. RayBiotech
  130. Redmile Group
  131. Regado Biosciences (A Subsidiary of Allergan)
  132. Rev1 Ventures
  133. Revelation Partners
  134. RIBOMIC
  135. Ritter Pharmaceuticals
  136. Samurai Incubate
  137. SB Management (A Subsidiary of SoftBank)
  138. SBI Group
  139. SBI Pharmaceuticals
  140. Seattle Children’s Research Institute
  141. Seikagaku
  142. Sekisui Diagnostics
  143. Showa Denko Materials
  144. SMBC Venture Capital
  145. SM-Sino Technology Investment
  146. SomaLogic
  147. Suzhou Ribo Life Science
  148. Synbio Technologies
  149. TAGCyx Biotechnologies
  150. Taisho Pharmaceutical
  151. Takeda
  152. The Ohio State University
  153. Tiger Gene
  154. Time BioVentures
  155. Tobira Therapeutics (Acquired by Allergan)
  156. Torres Quevedo Grant
  157. TriBiotica
  158. TriLink BioTechnologies (acquired by Maravai LifeSciences)
  159. Twist Bioscience
  160. Ulisse BioMed
  161. Univeristy College London
  162. University Health Network
  163. University of Hong Kong
  164. University of Louisville
  165. University of Manchester
  166. University of Tokyo
  167. Uppsala University Hospital
  168. UTokyo Innovation Platform
  169. ValitaCell
  170. Visium Healthcare Partners
  171. Vivonics
  172. WuXi STA (A Subsidiary of WuXi AppTec)
  173. Ziff Capital Healthcare Ventures

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com